Compounded hormone therapy: hidden safety and regulatory risks
Compounded hormone therapy carries a specific evidence problem: custom-made products do not undergo FDA premarket review for safety, efficacy, or dosing accuracy.
That leaves clinicians and patients without the same standardized evidence and quality controls available for FDA-approved hormone products.
The distinction matters because “bioidentical” describes a molecule, not the process used to make or regulate a drug. Some FDA-approved hormones are bioidentical to hormones produced by the human body. Compounded bioidentical hormone therapy (cBHT) is prepared by a compounding pharmacy and follows a different regulatory path.
The regulatory gap behind compounded hormone therapy risks
FDA-approved medications are reviewed before marketing for safety and efficacy, and their manufacturing is subject to established quality standards. Compounded hormone preparations do not go through that same premarket review. The FDA does not verify their safety, efficacy, or dosing accuracy before they reach patients.
Traditional 503A compounding pharmacies make customized preparations under a separate framework. That designation does not make a compounded hormone product FDA-approved. Nor does it provide the same premarket assurance of consistent strength and performance as an approved commercial product.
This is the central regulatory gap: the prescription may be individualized, but the resulting preparation does not acquire the evidence base or oversight attached to an FDA-approved drug.
The National Academies of Sciences, Engineering, and Medicine (NASEM) published a report on July 1, 2020, finding a lack of rigorous clinical evidence on the safety and effectiveness of cBHT. The report followed an FDA-commissioned study initiated in 2018. The evidence gap is not proof that every compounded prescription causes harm. It means that claims of equivalent or superior safety and efficacy are not established by robust clinical data.
Customization changes how a preparation is made. It does not substitute for premarket evidence or standardized quality control.
What ACOG’s guidance means in practice
The American College of Obstetricians and Gynecologists addressed compounded bioidentical menopausal hormone therapy in Clinical Consensus No. 6, published in November 2023. ACOG advises against routinely prescribing cBHT when FDA-approved options are available.
That recommendation is consistent with the underlying evidence problem. A clinician choosing a therapy needs to consider the indication, expected benefits, contraindications, dose, and available safety data. For a compounded product, the evidence supporting a particular preparation may be limited, while its manufacturing and dosing have not received FDA premarket review.
The Endocrine Society has also raised concerns about the lack of evidence and regulatory oversight for compounded hormone products. These positions do not mean that hormone therapy is inappropriate for everyone, or that all compounded prescriptions are identical. They do mean that a compounded product should not be assumed to offer a safer or more effective route simply because it is described as individualized or bioidentical.
If cBHT has been proposed, ask the prescriber to identify the clinical reason a compounded preparation is being considered and whether an FDA-approved option can meet the same treatment need. The answer should be specific to the medication and route, rather than based on a general claim that custom preparations are better.
Custom dosing and the limits of standardization
Compounding can serve a legitimate role when a commercially available drug cannot meet a patient’s clinical needs. But a customized formulation also introduces quality questions that are harder to answer without standardized product review.
The concerns include:
- Batch-to-batch variability. Compounded products may vary in potency or consistency between batches. FDA premarket review does not verify dosing accuracy for each compounded hormone preparation.
- Unvalidated dose selection. A prescription tailored to an individual does not itself prove that the selected dose has a favorable benefit-risk profile.
- Limited comparative evidence. NASEM found a lack of rigorous clinical evidence establishing the safety and effectiveness of cBHT. Long-term comparative safety data from prospective randomized trials directly comparing compounded formulations with FDA-approved hormone therapies are not established in the available evidence.
- Testing claims. Saliva or serum hormone testing is sometimes promoted as a way to personalize compounded formulations. Such testing has not been established as a medically validated method for tailoring cBHT in clinical guidelines.
These limitations matter because hormone exposure is not a cosmetic variable. The clinical effect depends on the hormone, dose, route, treatment goals, and a patient’s health profile. A label that presents a preparation as personalized cannot answer whether the dose is accurate or whether the treatment has been shown to produce the intended outcome.
Bioidentical does not mean compounded
The term “bioidentical” is often used as if it identifies a special category of unregulated, individually mixed hormones. It does not. It refers to hormones with a molecular structure identical to hormones produced in the human body.
FDA-approved products can contain bioidentical hormones. Examples include transdermal estradiol patches and oral micronized progesterone. These commercial products undergo testing and are manufactured under current good manufacturing practice standards. Their approved status does not mean they are risk-free or appropriate for every patient; it means their quality and use have been evaluated through a different process than cBHT.
| Feature | FDA-approved commercial hormone | Compounded hormone preparation |
|---|---|---|
| Premarket FDA review | Reviewed for safety and efficacy | No FDA premarket review for safety, efficacy, or dosing accuracy |
| Manufacturing standards | Subject to cGMP manufacturing requirements | Does not undergo the same FDA premarket product review |
| Bioidentical molecules | Some products, including estradiol and micronized progesterone, are bioidentical | May also contain bioidentical hormones |
| Evidence base | Product-specific review supports approved use | NASEM found a lack of rigorous evidence on cBHT safety and effectiveness |
| Adverse-event reporting | Follows applicable FDA reporting requirements | 503A pharmacies are not required to report adverse events to FDA |
The practical comparison is therefore not “natural versus synthetic.” It is a comparison between a product with FDA review and standardized manufacturing requirements and a preparation without that same premarket review.
Why adverse-event reporting is part of the safety issue
For traditional 503A pharmacies, adverse events associated with compounded hormone products are not subject to the same mandatory FDA reporting requirement that applies to FDA-approved drugs. These pharmacies are also not required to provide standardized package warnings detailing risks.
That creates a surveillance limitation. If an adverse event occurs after someone uses a compounded hormone, the available system may not capture it consistently. The precise nationwide incidence of adverse events caused specifically by 503A compounded hormone products is unknown, in part because mandatory centralized reporting is lacking.
This absence of reliable reporting should not be misread in either direction. It does not establish that compounded hormones cause more adverse events than commercial products. It also does not establish that they are equally safe. Without consistent reporting and strong comparative trials, the data cannot support a confident claim of superior safety.
Questions to take to a prescribing visit
A useful discussion focuses on the treatment decision and the evidence for the actual product. You can ask:
1. What hormone or symptom is the treatment intended to address, and what outcome should be monitored?
2. Is there an FDA-approved formulation with the same hormone and route?
3. What specific clinical need would require a compounded preparation?
4. How is the dose determined, and what evidence supports that dose?
5. What are the known risks, and how will possible adverse effects be assessed?
These questions do not replace an individualized medical evaluation. They make the regulatory and evidence differences visible before treatment begins. If a recommendation depends on claims that compounded hormones are inherently safer, more effective, or uniquely natural, ask what clinical evidence supports those claims.
The evidence-based bottom line
Compounded hormone therapy has regulatory and evidence limitations that should be part of informed prescribing. FDA premarket review does not cover compounded hormone preparations; batch consistency and dosing accuracy are not assured through the same process as for FDA-approved products; and adverse-event reporting for 503A pharmacies is not mandatory.
ACOG recommends against routinely prescribing compounded bioidentical menopausal hormone therapy when FDA-approved options exist. Some approved options are themselves bioidentical, so the word does not distinguish a compounded preparation from a regulated commercial medication.
The evidence supports a clear conclusion: cBHT has not been shown to be safer or more effective than FDA-approved hormone therapy. When an approved product can meet the clinical need, its established review and manufacturing framework provide a stronger basis for treatment decisions.